Trust Company of Vermont’s Karyopharm Therapeutics KPTI Stock Holding History

Trust Company of Vermont’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-27	Closed	-$4K	–	539
2021 Q2	$4K	Sell	27 -66	-71%	-$9.58K	﹤0.01%	708
2021 Q1	$15K	Hold	93	–	–	﹤0.01%	588
2020 Q4	$22K	Hold	93	–	–	﹤0.01%	531
2020 Q3	$20K	Sell	93 -40	-30%	-$9.78K	﹤0.01%	527
2020 Q2	$38K	Hold	133	–	–	﹤0.01%	465
2020 Q1	$38K	Buy	133 +26	+24%	+$7.17K	﹤0.01%	471
2019 Q4	$31K	Hold	107	–	–	﹤0.01%	534
2019 Q3	$16K	Hold	107	–	–	﹤0.01%	670
2019 Q2	$10K	Buy	107 +34	+47%	+$2.73K	﹤0.01%	749
2019 Q1	$7K	Buy	73 +33	+83%	+$3.66K	﹤0.01%	759
2018 Q4	$6K	Buy	+40	New	+$6.75K	﹤0.01%	810

Other funds holding KPTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trust Company of Vermont's KPTI Position: Q3 2021 in Review

Trust Company of Vermont sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 27 shares — an estimated $4K sold.

Trust Company of Vermont first reported a position in KPTI in Q4 2018 and held it in 11 quarters. The position peaked at $38K in Q2 2020. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

Trust Company of Vermont reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
Trust Company of Vermont sold 27 Karyopharm Therapeutics shares in Q3 2021, an estimated $4K.
Trust Company of Vermont first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 11 quarters.
Trust Company of Vermont's Karyopharm Therapeutics position peaked at $38K in Q2 2020.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Trust Company of Vermont's 13F filing for Q3 2021, filed 22 Oct 2021.